Integra LifeSciences Holdings Corporation (IART)

Market Cap	2.24B
Revenue (ttm)	1.54B
Net Income (ttm)	67.74M
Shares Out	78.22M
EPS (ttm)	0.84
PE Ratio	34.14
Forward PE	8.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,916,227
Open	31.72
Previous Close	31.63
Day's Range	27.85 - 31.72
52-Week Range	27.85 - 59.10
Beta	1.14
Analysts	Buy
Price Target	45.00 (+56.9%)
Earnings Date	May 6, 2024

About IART

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and ins...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Aug 16, 1995
• Employees: 3,946
• Stock Exchange: NASDAQ
• Ticker Symbol: IART

Financial Performance

In 2023, IART's revenue was $1.54 billion, a decrease of -1.03% compared to the previous year's $1.56 billion. Earnings were $67.74 million, a decrease of -62.48%.

Analyst Forecast

According to 9 analysts, the average rating for IART stock is "Buy." The 12-month stock price forecast is $45.0, which is an increase of 56.90% from the latest price.

Price Target

$45.0

(56.90% upside)

Analyst Consensus: Buy